Cargando…

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD

Detalles Bibliográficos
Autores principales:	Myers, Kelly D., Wilemon, Katherine, McGowan, Mary P., Howard, William, Staszak, David, Rader, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387291/ https://www.ncbi.nlm.nih.gov/pubmed/34611637 http://dx.doi.org/10.1016/j.ajpc.2021.100197

Ejemplares similares

Letter to the Editor in response to “Response to Kovanen PT, et al. Letter to the Editor” for original article COVID-19 increases risk of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

A proof-of-concept study of cascade screening for Familial Hypercholesterolemia in the US, adapted from the Dutch model
por: McGowan, Mary P., et al.
Publicado: (2021)

Yield of Familial Hypercholesterolemia Genetic and Phenotypic Diagnoses After Electronic Health Record and Genomic Data Screening
por: Gidding, Samuel S., et al.
Publicado: (2023)

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry
por: Cuchel, Marina, et al.
Publicado: (2023)

Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
por: Myers, Kelly D., et al.
Publicado: (2019)

Familial hypercholesterolemia in very young myocardial infarction
por: Li, Sha, et al.
Publicado: (2018)

Finding missed cases of familial hypercholesterolemia in health systems using machine learning
por: Banda, Juan M., et al.
Publicado: (2019)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis: Identification Methods, Patient Activation, and Cascade Testing for Familial Hypercholesterolemia
por: Campbell-Salome, Gemme, et al.
Publicado: (2021)

Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction
por: Cui, Yuxia, et al.
Publicado: (2019)

Genetic Determinants of Myocardial Infarction Risk in Familial Hypercholesterolemia
por: Zhao, Pei Jun, et al.
Publicado: (2019)

Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia
por: Campbell-Salome, Gemme, et al.
Publicado: (2023)

Whole-exome sequencing in an extended family with myocardial infarction unmasks familial hypercholesterolemia
por: Brænne, Ingrid, et al.
Publicado: (2014)

Patient experiences align with the familial hypercholesterolemia global call to action
por: Jones, Laney K., et al.
Publicado: (2022)

Effects of familial hypercholesterolemia-associated genes on the phenotype of premature myocardial infarction
por: Lee, Chongyou, et al.
Publicado: (2019)

A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
por: Srivastava, Rai Ajit K.
Publicado: (2023)

Highlights in ASCVD Primary Prevention for 2021
por: Polonsky, Tamar S., et al.
Publicado: (2022)

Familial hypercholesterolemia supravalvular aortic stenosis and extensive atherosclerosis
por: Prajapati, Rajpal, et al.
Publicado: (2018)

Predictors of Family Recruitment in a Program of Genetic Cascade Screening for Familial Hypercholesterolemia
por: Izar, Maria Cristina de Oliveira, et al.
Publicado: (2018)

The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry
por: Shi, Hui-Wei, et al.
Publicado: (2020)

Gauging ASCVD Risk, Does Race Matter?
por: Zuo, Ming-Liang, et al.
Publicado: (2022)

Health Literacy is Essential to ASCVD Prevention in Youth
por: Mann, Harnoor K., et al.
Publicado: (2023)

Association of hyperuricemia combined with sarcopenia on ASCVD risk
por: Nie, Guqiao, et al.
Publicado: (2023)

Corrigendum: The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry
por: Shi, Hui-Wei, et al.
Publicado: (2020)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

Renal and Splenic Infarction in a Patient with Familial Hypercholesterolemia and Previous Cerebral Infarction
por: el Barzouhi, Abdelilah, et al.
Publicado: (2018)

Acute myocardial infarction and transient elevated anticardiolipin antibody in a young adult with possible familial hypercholesterolemia: a case report: Anticardiolipin antibody and myocardial infarction
por: Su, Xin, et al.
Publicado: (2019)

Acute myocardial infarction in an 18 year old South Indian girl with familial hypercholesterolemia: a case report
por: Kumar, Anita A, et al.
Publicado: (2008)

Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
por: Kovanen, Petri T., et al.
Publicado: (2021)

Designing implementation strategies to improve identification, cascade testing, and management of families with familial hypercholesterolemia: An intervention mapping approach
por: Jones, Laney K., et al.
Publicado: (2023)

Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey
por: Yao, Hermann, et al.
Publicado: (2021)

Prevalence of genetically defined familial hypercholesterolemia and the impact on acute myocardial infarction in Taiwanese population: A hospital-based study
por: Chen, Yen-Ju, et al.
Publicado: (2022)

Familial Hypercholesterolemia
por: Baruah, Dibya Kumar
Publicado: (2021)

Genetically confirmed familial hypercholesterolemia in outpatients with hypercholesterolemia
por: Wang, Xu, et al.
Publicado: (2018)

Can Non-Pharmacological Treatment Promote Additional Benefit for Children with Familial Hypercholesterolemia Treated with Statins?
por: Antoniazzi, Luiza
Publicado: (2018)

A substitution mutation in LRP8 gene is significantly associated with susceptibility to familial myocardial infarction
por: Ghorbani, Mohammad Javad, et al.
Publicado: (2020)

Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
por: Jarauta, Estíbaliz, et al.
Publicado: (2020)

The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers
por: Choi, Seonghoon
Publicado: (2019)

Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals
por: Enas, Enas A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_scs6tlgmb82b738fbrnmne9b2s